ICYMI: Report highlights overall decrease in cancer death rates

Andrew Powaleny   |     April 3, 2017   |   SHARE THIS

In case you missed it, cancer death rates are continuing to decrease for men, women and children in the United States thanks in part to biopharmaceutical innovation, according to the Annual Report to the Nation on the Status of Cancer.

Published annually by The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute and the North American Association of Central Cancer Registries, the report found from 2010 to 2014, cancer death rates decreased each year by 1.8 percent in men, 1.4 percent in women and 1.6 percent in children.

The report notes:

  • Death rates decreased for 11 of the 16 most common cancer types in men and for 13 of the 18 most common cancer types in women, including lung, colorectal, female breast, and prostate.
  • When comparing data from 1975 to 1977 and 2006 to 2012, the report found the five-year survival rates for some distant-stage types of cancer increased significantly. For example, the survival rate for distant-stage breast cancer in women jumped from 18.7 percent to 33.6 percent.

With improved early detection and more effective treatments, efforts to improve cancer outcomes are seeing positive results.

While cancers persist as some of the most complex and devastating disease areas, biopharmaceutical researchers remain committed to continuing the progress toward better treatments and cures for the more than 200 unique diseases we call cancer. Researchers continue to better understand the underlying complexity of cancers, and today, there are more than 800 medicines and vaccines in clinical testing for cancer – approximately 80 percent of which are potentially the first of their kind.

Read more about the work being done by America’s biopharmaceutical companies in cancer treatment and about the last decade of innovation in cancer.

Andrew Powaleny

Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly runs with the DC Front Runners and serves as its co-race director. He is also a member of the National Lesbian Gay Journalists Association and a proud alum of The Fund for American Studies. He’s passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Topics: Cancer

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates